Gain Therapeutics Inc (GANX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Gain Therapeutics inc  (NASDAQ: GANX)


Gain Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Gain Therapeutics Inc's ROI in the second quarter of 2026?
Gain Therapeutics Inc recorded a cumulative net loss of $-20 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -150.41%.

Within the Healthcare sector 677 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3468 to 4228.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 79.79 % 23.02 % -4.86 % -41.11 % -32.77 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 12 15 20 7 5
Return On Investment (TTM) -150.41 % -183.58 % -210.71 % -288.36 % -250.06 %
GANX's Overall Ranking # 4228 # 3468 # 3691 # 3670 # 3520
Seq. Investment Change TTM 15.54 % 20.92 % 42.28 % -9.56 % -20.94 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -20 -21 -20 -19 -19

GANX Company Profile >> Back to GANX Roi Comparisons >> See Annual GANX Return On Investment



Return On Investment GANX's Ranking
Within: No.
Industry # 309
Sector # 678
Overall # 4228

Return On Investment Statistics
High Average Low
-21.27 %
-142.43 %
-285.79 %
(Mar 31 2021)   (Sep 30 2025)



  News about Gain Therapeutics inc Return on Investment ROI

Gain Therapeutics CEO Matthias Alder Highlights Growth Potential and Future Plans for Shareholders

January 31, 2024



Gain Therapeutics, a renowned biotechnology company pioneering the breakthrough discovery and development of allosteric small molecule therapies, has recently provided an operational update through a letter addressed to shareholders from its President and Chief Executive Officer, Matthias Alder. The letter sheds light on the company s progress, achievements, and future prospects. Despite recording a net loss of $22 million in the previous year, Gain Therapeutics remains optimistic and committed to delivering innovative medical advancements in the field of healthcare.

In his letter, Matthias Alder acknowledges the shareholders continued support and expresses his confidence in the company s ability to drive meaningful change and contribute to the healthcare sector. Despite facing some financial setbacks, Gain Therapeutics has exhibited resilience and a focused approach to transforming the lives of patients through its groundbreaking therapies.





Financial Statements
Gain Therapeutics Inc's II. Quarter Investments $ 12 Millions GANX's Balance sheet
Gain Therapeutics Inc's II. Quarter Income $ -5 Millions Quarterly GANX's Income Statement
GANX's Income by Division See GANX's Income by Division


GANX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 19 8 14 20 36
Y / Y Investment Growth 134.46 % -39.88 % -30.07 % -45.34 % -
Net Income in Millions -20 -20 -22 -18 -14
Y / Y Net Income Growth - - - - -
Annual Return On Investment -104.7 % -248.54 % -163.02 % -90.06 % -38.87 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
GANX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for GANX's Competitors
Subscribers only: Roi for Gain Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for GANX's Customers

Other Ratios
GANX's Roa GANX's Inventory Turnover Ratio GANX's Growth Rates GANX's Dividend Statistics
GANX's Profitability Ratios GANX's Asset Turnover Ratio GANX's Dividend Growth
GANX's Roe GANX's Valuation Ratios GANX's Financial Strength Ratios GANX's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-08T17:52:08+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.